These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30113232)

  • 1. Hereditary cancer testing challenges: assembling the analytical pieces to solve the patient clinical puzzle.
    Bowles KR; Mancini-DiNardo D; Coffee B; Cox HC; Qian Y; Elias M; Singh N; Judkins T; Leclair B; Roa BB
    Future Oncol; 2019 Jan; 15(1):65-79. PubMed ID: 30113232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing.
    Silva-Smith R; Sussman DA
    Fam Cancer; 2018 Jan; 17(1):87-90. PubMed ID: 28600700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes.
    Soukupova J; Zemankova P; Lhotova K; Janatova M; Borecka M; Stolarova L; Lhota F; Foretova L; Machackova E; Stranecky V; Tavandzis S; Kleiblova P; Vocka M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z
    PLoS One; 2018; 13(4):e0195761. PubMed ID: 29649263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Lynch Syndrome and Associated Endometrial Cancer.
    Tafe LJ
    J Mol Diagn; 2015 Sep; 17(5):472-82. PubMed ID: 26162329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients.
    Lincoln SE; Kobayashi Y; Anderson MJ; Yang S; Desmond AJ; Mills MA; Nilsen GB; Jacobs KB; Monzon FA; Kurian AW; Ford JM; Ellisen LW
    J Mol Diagn; 2015 Sep; 17(5):533-44. PubMed ID: 26207792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening.
    Frey MK; Kim SH; Bassett RY; Martineau J; Dalton E; Chern JY; Blank SV
    Gynecol Oncol; 2015 Nov; 139(2):211-5. PubMed ID: 26296696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
    Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
    BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-Source Bioinformatic Pipeline to Improve PMS2 Genetic Testing Using Short-Read NGS Data.
    Munté E; Feliubadaló L; Del Valle J; González S; Ramos-Muntada M; Balmaña J; Ramon Y Cajal T; Tuset N; Llort G; Cadiñanos J; Brunet J; Capellá G; Lázaro C; Pineda M
    J Mol Diagn; 2024 Aug; 26(8):727-738. PubMed ID: 38851388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines.
    Marcus RK; Geurts JL; Grzybowski JA; Turaga KK; Clark Gamblin T; Strong KA; Johnston FM
    Fam Cancer; 2015 Dec; 14(4):641-9. PubMed ID: 26108897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Mutation Analysis of PMS2 in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome.
    van der Klift HM; Mensenkamp AR; Drost M; Bik EC; Vos YJ; Gille HJ; Redeker BE; Tiersma Y; Zonneveld JB; García EG; Letteboer TG; Olderode-Berends MJ; van Hest LP; van Os TA; Verhoef S; Wagner A; van Asperen CJ; Ten Broeke SW; Hes FJ; de Wind N; Nielsen M; Devilee P; Ligtenberg MJ; Wijnen JT; Tops CM
    Hum Mutat; 2016 Nov; 37(11):1162-1179. PubMed ID: 27435373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene panel testing for inherited cancer risk.
    Hall MJ; Forman AD; Pilarski R; Wiesner G; Giri VN
    J Natl Compr Canc Netw; 2014 Sep; 12(9):1339-46. PubMed ID: 25190699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing.
    Rohlin A; Rambech E; Kvist A; Törngren T; Eiengård F; Lundstam U; Zagoras T; Gebre-Medhin S; Borg Å; Björk J; Nilbert M; Nordling M
    Fam Cancer; 2017 Apr; 16(2):195-203. PubMed ID: 27696107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular genetic methods used in diagnosis of hereditary cancers].
    Patócs A
    Magy Onkol; 2020 Mar; 64(1):25-31. PubMed ID: 32181759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.
    Castellanos E; Gel B; Rosas I; Tornero E; Santín S; Pluvinet R; Velasco J; Sumoy L; Del Valle J; Perucho M; Blanco I; Navarro M; Brunet J; Pineda M; Feliubadaló L; Capellá G; Lázaro C; Serra E
    Sci Rep; 2017 Jan; 7():39348. PubMed ID: 28051113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a Next-Generation Sequencing Pipeline for the Molecular Diagnosis of Multiple Inherited Cancer Predisposing Syndromes.
    Paulo P; Pinto P; Peixoto A; Santos C; Pinto C; Rocha P; Veiga I; Soares G; Machado C; Ramos F; Teixeira MR
    J Mol Diagn; 2017 Jul; 19(4):502-513. PubMed ID: 28529006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus document on the implementation of next generation sequencing in the genetic diagnosis of hereditary cancer.
    Soto JL; Blanco I; Díez O; García Planells J; Lorda I; Matthijs G; Robledo M; Souche E; Lázaro C
    Med Clin (Barc); 2018 Jul; 151(2):80.e1-80.e10. PubMed ID: 29439875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptability of, and Information Needs Regarding, Next-Generation Sequencing in People Tested for Hereditary Cancer: A Qualitative Study.
    Meiser B; Storey B; Quinn V; Rahman B; Andrews L
    J Genet Couns; 2016 Apr; 25(2):218-27. PubMed ID: 26259529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principles of molecular testing for hereditary cancer.
    Mighton C; Lerner-Ellis JP
    Genes Chromosomes Cancer; 2022 Jun; 61(6):356-381. PubMed ID: 35436018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic testing for cancer predisposition.
    Eng C; Hampel H; de la Chapelle A
    Annu Rev Med; 2001; 52():371-400. PubMed ID: 11160785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole Exome Sequencing: The Next Phase of Genetics Care.
    Mahon SM
    Oncol Nurs Forum; 2016 Mar; 43(2):249-52. PubMed ID: 26906136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.